Clinical Solutions

Translating Research into Real-World Impact

The GPM group is dedicated to bridging the gap between cutting-edge cancer research and real-world clinical application. By translating multi-omics data and advanced computational insights into actionable diagnostics and therapies, we empower clinicians with precision tools that improve patient outcomes. Our approach leverages state-of-the-art molecular oncology programs, including the Integrated Laboratory Pipeline (ILP) and the Molecular Precision Oncology Program (MPOP) at DKFZ and NCT, alongside HI-STEM’s expertise in stem cell and translational medicine.

Through collaboration with multi-centric precision oncology clinical studies involving thousands of patients, GPM intents to integrate comprehensive genomic profiling with clinical decision-making. This facilitates personalized treatment selection, early detection of therapy resistance, and development of novel targeted therapies.

Clinical Approach Highlights:

Collaborating to Advance Clinical Genomics Solutions:

GPM works closely with DKFZ, NCT and HI-STEM teams to adapt and expand clinical genomics workflows, such as whole genome sequencing (WGS), transcriptomics, and molecular profiling, toward globally inclusive applications. By building on programs like CATCH, COGNITION, and MASTER, GPM aims to develop new assays and interpretation pipelines that capture the genetic diversity of worldwide cancer patients, enabling better-informed personalized therapies.

Integrating Multi-Omics & AI for Enhanced Clinical Decision-Making:

Leveraging state-of-the-art AI-driven platforms, GPM integrates heterogeneous molecular data to generate actionable clinical insights rapidly. While DKFZ’s ILP currently streamlines data processing and reporting, GPM’s objective is to collaborate on next-generation platforms that improve speed, accuracy, and applicability for global populations, ensuring that precision oncology can be effective and scalable beyond current geographies.

Expanding Access to Globally Relevant Clinical & Genomic Data:

GPM prioritizes the collection and analysis of clinical and sequencing data from underrepresented populations worldwide. By partnering with international hospitals, government agencies  and research centres, GPM enhances data inclusivity and supports the development of precision medicine tools tailored to diverse genetic backgrounds. This global focus helps identify new biomarkers and resistance patterns, ensuring equitable cancer care innovations.